NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial
Université Paris Sciences et Lettres · Institut Curie · +37 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
493
total citations
- FWCI
- 37.15
- Percentile
- 100%
- References
- 41
Citations per year
Authors
42- SBSylvie BonvalotCorresponding
Université Paris Sciences et Lettres, Institut Curie
- PRPiotr Rutkowski
The Maria Sklodowska-Curie National Research Institute of Oncology
- JTJuliette Thariat
Centre François Baclesse, Centre François Baclesse, Centre Antoine Lacassagne
- SCSébastien Carrère
Gefluc Languedoc Roussillon
- ADAnne Ducassou
Institut Claudius Regaud
Topics & keywords
Topics
Keywords
- Medicine
- Radiation therapy
- Soft tissue sarcoma
- Sarcoma
- Clinical endpoint
- Population
- Clinical trial
- Randomized controlled trial
No related works found for this paper.